The better prognosis in SCC/LCNEC may relate to preserved neuroendocrine differentiation and pathway genes of SCLC (TP53/RB1) and NSCLC (STK11/KEAP1/RAS), potentially enhancing sensitivity to platinum-based regimens (41). This evidence concerns the gene STK11 and large cell neuroendocrine carcinoma.